Biofrontera Inc (BFRI)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $10.40M
Last updated: Nov 17, 2026 at 11:02 AM ET
Biofrontera Inc (BFRI) Earnings: Report Dates and Results
Biofrontera (BFRI) is expected to report earnings on Mar 16, 2027. In the quarter ended Sep 30, 2026, Biofrontera reported EPS of -$0.42, below the -$0.11 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
BFRI has an expected report date of Mar 16, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 36.0% below the $0.50 reported for the quarter ended Dec 31, 2025.
BFRI Earnings Call
The latest BFRI earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 21 quarters below that had an estimate, BFRI beat 9 and missed 12. Revenue for the quarter ended Sep 30, 2026 was $9.07M, up 29.8% from $6.99M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.42 | -$0.11 | -$0.11 - -$0.11 | -281.82% | Miss | N/A | 1 | 1 up, 0 down | Nov 13, 2026 | $9.07M |
| Jun 30, 2026 | -$0.05 | -$0.17 | N/A | +70.59% | Beat | N/A | 1 | 1 up, 0 down | Aug 13, 2026 | $12.00M |
| Mar 31, 2026 | -$0.41 | -$0.05 | -$0.05 - -$0.05 | -720.00% | Miss | N/A | 1 | 1 up, 0 down | May 14, 2026 | $10.08M |
| Dec 31, 2025 | $0.50 | $0.10 | $0.10 - $0.10 | +400.00% | Beat | N/A | 1 | 0 up, 1 down | Mar 19, 2026 | $17.10M |
| Sep 30, 2025 | -$0.57 | -$0.56 | -$0.56 - -$0.56 | -1.79% | Miss | N/A | 1 | 0 up, 1 down | Nov 12, 2025 | $6.99M |
| Jun 30, 2025 | -$0.57 | -$0.39 | -$0.39 - -$0.39 | -46.15% | Miss | N/A | 1 | 1 up, 0 down | Aug 13, 2025 | $9.03M |
| Mar 31, 2025 | -$0.47 | -$0.14 | N/A | -235.71% | Miss | N/A | 1 | 0 up, 1 down | May 15, 2025 | $8.59M |
| Dec 31, 2024 | -$0.23 | -$0.07 | -$0.07 - -$0.07 | -231.43% | Miss | N/A | 1 | 1 up, 0 down | Mar 21, 2025 | $12.56M |
| Sep 30, 2024 | -$0.81 | -$0.94 | -$0.94 - -$0.73 | +13.83% | Beat | N/A | 2 | 0 up, 0 down | Nov 13, 2024 | $9.01M |
| Jun 30, 2024 | -$1.08 | -$0.35 | -$1.19 - -$0.35 | -208.57% | Miss | N/A | 2 | 0 up, 0 down | Aug 14, 2024 | $7.84M |
| Mar 31, 2024 | -$2.88 | -$1.17 | -$1.63 - -$0.71 | -146.15% | Miss | N/A | 2 | 0 up, 0 down | May 15, 2024 | $7.91M |
| Dec 31, 2023 | -$0.68 | -$0.85 | -$1.53 - -$0.85 | +20.00% | Beat | N/A | 2 | 0 up, 0 down | Mar 15, 2024 | $10.59M |
| Sep 30, 2023 | -$3.16 | -$3.34 | -$4.23 - -$3.34 | +5.39% | Beat | N/A | 2 | 1 up, 0 down | Nov 9, 2023 | $8.90M |
| Jun 30, 2023 | -$6.07 | -$4.08 | -$5.14 - -$4.08 | -48.77% | Miss | N/A | 2 | 0 up, 0 down | Aug 11, 2023 | $5.85M |
| Mar 31, 2023 | -$3.22 | -$3.40 | -$4.40 - -$3.40 | +5.29% | Beat | N/A | 2 | 0 up, 0 down | May 12, 2023 | $8.73M |
| Dec 31, 2022 | -$0.14 | -$0.11 | -$0.13 - -$0.09 | -27.27% | Miss | N/A | 2 | 0 up, 0 down | Mar 7, 2023 | $10.14M |
| Sep 30, 2022 | -$5.24 | -$5.80 | -$6.40 - -$5.20 | +9.66% | Beat | N/A | 2 | 0 up, 0 down | Nov 14, 2022 | $4.32M |
| Jun 30, 2022 | -$8.63 | -$6.80 | -$7.40 - -$6.20 | -26.91% | Miss | N/A | 2 | 0 up, 1 down | Aug 12, 2022 | $4.46M |
| Mar 31, 2022 | -$6.11 | -$3.60 | N/A | -69.72% | Miss | N/A | 1 | 2 up, 0 down | Apr 8, 2022 | $9.75M |
| Dec 31, 2021 | -$0.15 | -$0.18 | -$0.20 - -$0.16 | +16.67% | Beat | N/A | 2 | 0 up, 1 down | Dec 31, 2021 | $9.17M |
| Sep 30, 2021 | -$9.66 | -$11.60 | -$11.60 - -$11.60 | +16.72% | Beat | N/A | 1 | 0 up, 0 down | Nov 1, 2021 | $4.33M |
| Jun 30, 2021 | -$0.51 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jul 6, 2021 | $5.86M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.11, after -$5.00 the year before. It was -$10.32 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.11 | N/A |
| Dec 31, 2024 | -$5.00 | N/A |
| Dec 31, 2023 | -$13.13 | N/A |
| Dec 31, 2022 | -$20.12 | N/A |
| Dec 31, 2021 | -$10.32 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,700 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 3,668 | 6 | |
| 2026Q2 | Jun 30, 2026 | 4,250 | 7 | |
| 2026Q1 | Mar 31, 2026 | 3,614 | 7 | |
| 2025Q4 | Dec 31, 2025 | 3,570 | 6 | |
| 2025Q3 | Sep 30, 2025 | 2,705 | 5 | |
| 2025Q2 | Jun 30, 2025 | 3,634 | 6 | |
| 2025Q1 | Mar 31, 2025 | 2,290 | 6 | |
| 2024Q3 | Sep 30, 2024 | 3,245 | 6 |
2026Q3 Earnings Call
Opening remarks
Ben Shamsian Investor Relations Representative Good morning, and welcome to Biofrontera's Third Quarter 2026 Financial Results and Business Update Conference Call. Please note that certain information discussed during today's call by management is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that Biofrontera's management will be making forward-looking statements and that actual results may differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. Forward-looking statements on today's call include statements regarding the timing and success of the commercial launch of Ameluz for superficial basal cell carcinoma; the company's supplemental new drug application for actinic keratosis on the extremities, neck, and trunk; the effects of the International Trade Commission orders; the company's remediation plan and the RhodoLED XLC; the outcome of pending appeals and patent proceedings; the company's liquidity, its ability to continue as a going concern, and its plans to address that condition; and the company's compliance with NASDAQ continued listing standards. All risks and uncertainties are detailed in and qualified by the cautionary statements contained in Biofrontera's press releases and SEC filings, including the company's quarterly report on Form 10-Q for the quarter ended September 30, 2026, which the company expects to file later today, and the company's annual report on Form 10-K for the year ended December 31, 2025. Also, this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast. Biofrontera undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as required by law. During today's call, there will be references to certain non-GAAP financial measures. Biofrontera believes these measures provide information for investors, but they should not be considered a substitute for GAAP or viewed as a substitute for operating results determined in accordance with GAAP. A reconciliation of non-GAAP to GAAP results is included in the press release issued today and is available on the company's website at www.biofronteraus.com under the Investor Relations section. Please note management will be referencing adjusted EBITDA, a non-GAAP financial measure defined as net loss excluding interest expense, net income taxes, depreciation and amortization, and certain other nonrecurring or noncash items, including changes in fair value of warrant liabilities and of the related-party investment, patent remediation expense, ITC-related inventory write-downs, and stock-based compensation. With that said, I would now like to turn the call over to Hermann Luebbert, CEO, Chairman, and Founder of Biofrontera. Hermann.
Operator Operator Please proceed. Sir, is your line on mute, perhaps?
Hermann Luebbert CEO, Chairman, and Founder Yes. I was on mute. Thank you, Ben, and thanks, everyone, for joining us this morning.
Frequently Asked Questions About BFRI
When is Biofrontera's next earnings date?
Biofrontera's next earnings report is expected for Mar 16, 2027.
Did BFRI beat earnings estimates last quarter?
No. Biofrontera reported EPS of -$0.42 for the quarter ended Sep 30, 2026, below the -$0.11 estimate by 281.82%.
What EPS do analysts expect from BFRI next quarter?
The consensus EPS estimate for Biofrontera for the quarter ending Dec 31, 2026 is $0.32 from 3 analysts, with estimates from $0.30 to $0.33.
How often does BFRI beat earnings estimates?
Biofrontera beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -130.79%.
BFRI pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts